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toxicity in cancer 
Abstract
Low muscle mass in individuals with cancer has a profound impact on quality of life and 
independence, and is associated with greater treatment toxicity and poorer prognosis. Exercise 
interventions are regularly being investigated as a means to ameliorate treatment-related adverse 
effects, and nutrional/supplementation strategies to augment adaptations to exercise are highly 
valuable. Creatine (Cr) is a naturally-occurring substance in the human body that plays a critical 
role in energy provision during muscle contraction. Given the beneficial effects of Cr 
supplementation on lean body mass, strength, and physical function in a variety of clinical 
populations, there is therapeutic potential in individuals with cancer at heightened risk for muscle 
loss. Here, we provide an overview of Cr physiology, summarize the evidence on the use of Cr 
supplementation in various aging/clinical populations, explore mechanisms of action, and provide 
perspectives on the potential therapeutic role of Cr in the exercise oncology setting.
Keywords: oncology, cachexia, body composition, muscle, bone, strength, resistance training, 
21.Introduction
Individuals with cancer are at a high risk of skeletal muscle wasting that may be exacerbated by 
tumor-related factors and cancer therapies (certain hormone and chemotherapies in particular) [1-
7]. An emerging body of literature supports the role of exercise as a means to ameliorate these 
treatment-related declines and improve clinically relevant patient outcomes [7-10]. Indeed, the 
existing evidence is that progressive resistance training (PRT) can improve physical function, 
muscle strength and body composition in patients undergoing a variety of treatments [10-16]. 
Nevertheless, given the implications of low muscle mass on treatment toxicity and prognosis, 
identifying strategies to enhance adaptations to exercise training in a cancer population are of both 
clinical benefit and importance [17-20]. More recently, there has been an increasing appreciation 
for the role of nutritional and dietary supplement interventions, both alone and with exercise, to 
maintain or improve clinically relevant outcomes and augment training adaptations in cancer 
patients [21-24].
Creatine (Cr) is one of the most extensively studied supplements, with research demonstrating its 
efficacy to augment lean body mass (LBM) accretion, increase muscle strength, and improve 
physical function in a variety of healthy and clinical populations [25]. More recently, Cr 
supplementation has gained attention in the medical field as a result of the beneficial effects found 
in numerous muscular and neurological diseases, such as McArdle disease, Duchenne dystrophy, 
myasthenis gravis, amyotrophic lateral sclerosis, and Parkinson’s disease [17, 26, 27]. Given the 
potent additive effects of Cr on muscle performance and LBM, it’s unsurprising that Cr is now 
being considered as a therapeutic aid in some cancer contexts [28]. Nevertheless, supplementation 
with Cr in a cancer context, particularly in human participants, is notably sparse. Paucity of 
3research in this area may stem from lack of awareness of the potential role of Cr supplementation 
in a cancer setting, misunderstanding of mechanisms of action, safety concerns from unfounded 
media reports, or a combination of the above.  Thus, the purpose of this narrative review is to 
provide: (1) an overview of Cr physiology; (2) summarize studies investigating the therapeutic use 
of Cr supplementation in cancer and other clinical populations; (3) provide perspectives on the 
potential therapeutic role of Cr supplementation to treat cancer-related physical impairments, (4) 
identify specific types of cancer groups that may benefit the most from supplementation and (5) 
offer suggestions for future research.
2.Creatine metabolism
Cr is a naturally-occurring substance in the human body, synthesized endogenously in the kidneys, 
pancreas and liver at a rate of ~1-2 g/day [29]. Additionally, approximately 1 gram of Cr can be 
consumed by individuals with a diet high in meat and fish [30]. The majority of Cr (95%) is stored 
in skeletal muscle (as free creatine or phosphocreatine), with the rest found in the brain and testes 
[25]. Approximately 2 g/day of Cr is lost as creatinine in urine. Given that rates of excretion 
typically match levels of endogenous production and intake, the most efficient way to increase 
intramuscular Cr stores is through supplementation [30].
Cr is a component of the high-energy phosphate, phosphocreatine (PCr), which plays a critical role 
in rapid energy provision during skeletal muscle contraction [21]. Re-phosphorylation of 
adenosine diphosphate (ADP) to adenosine triphosphate (ATP) during and following exercise 
(Figure 1) is reliant on the amount of PCr stored in the muscle (PCr + ADP ↔  Cr + ATP) [25]. 
4In addition to its role as a temporal energy buffer, PCr acts as a spatial energy buffer to shuttle 
high-energy phosphates between mitochondria and cellular ATP utilization sites [31].
Fig 1. Phosphocreatine shuttle system. Creatine catalyzes reversible phosphorylation of creatine 
to Phosphocreatine and ADP to ATP.  (print in color)
It is hypothesized that Cr uptake by skeletal muscle is modulated by muscle activity [32]. As PCr 
availability diminishes with intense exercise, ability to sustain exercise effort declines accordingly. 
Further, an increase in availability of PCr may allow for accelerated resynthesis of ATP during 
exercise [25, 33].  In this manner, PCr content in the muscle may be an important regulator of 
exercise capacity. As a result, the ergogenic effects of Cr supplementation are likely an increase 
in intramuscular PCr [32, 34], enhancing exercise capacity, and leading to an increase in training 
quality and overall training volume [25, 33]. In other words, an increase in the body’s Cr stores 
may allow for better recovery between sets of exercises or repeated efforts, allowing the individual 
to perform more higher quality work and receive a better “dose” of exercise. When done 
consistently, this can add up to potentially greater improvements in LBM and strength compared 
to exercise alone.
53.Creatine supplementation in healthy aging/clinical populations
This section is not intended to be an exhaustive review of the relevant literature examining Cr 
supplementation in healthy aging/clinical populations. Rather, it is intended to outline the efficacy 
of Cr supplementation using select studies representative of the broader body of literature in 
improving relevant cancer-related outcomes (sarcopenia, loss of strength, bone health and physical 
function) that are experienced in other populations. Studies were chosen based on research design 
(randomised, double-blind, placebo-controlled), form of creatine used (creatine monohydrate), 
population being studied (clinical patients and older adults), and dependent variable reported (body 
composition and physical function).  Indeed, more comprehensive reviews of Cr supplementation 
are available in healthy aging [35-37], neurodegenerative [36, 38] and muscular disorders [39].
3.1Healthy aging
Aging is associated with an incremental loss in muscle mass, physical function, and independence. 
Additionally, intramuscular stores of creatine are ~25% lower in older [40] and middle-aged adults 
[41] than younger individuals. However, individuals with low intramuscular total Cr 
concentrations show an enhanced ability to increase creatine content following Cr supplementation 
[32]. Cr supplementation has been shown to increase muscle strength and function, enhance fatigue 
resistance, and improve performance in activities of daily living irrespective of exercise training 
in older populations [42, 43]. A summary of the studies discussed in this review examining Cr 
supplementation in healthy aging/clinical populations are presented in Table 1.
Stout et al. [42] found significant increases in handgrip strength and physical working capacity 
among elderly men and women supplementing with Cr for 14 days. The significant delay in the 
6onset of neuromuscular fatigue, as measured by the physical working capacity (PWCFT) test, may 
have been due to elevated muscle PCr content, which can decrease the reliance on anaerobic 
glycolysis, reduce intramuscular lactate and ammonia accumulation, and therefore delay fatigue. 
Short-term Cr supplementation has also been shown to improve upper and lower body muscular 
strength. Gotshalk et al. [44] reported significant increases in bench press (4.11.4 kg) and leg 
press (16.14.4 kg) strength, as well as significant improvements in lower body mean power and 
timed sit-to-stand following 7 days of Cr supplementation in older men [45]. Supporting these 
findings, Canete et al. [44] demonstrated a 12% improvement in timed sit-to-stand following 7 
days of Cr supplementation in older women. 
Cr supplementation in conjunction with PRT can result in greater adaptations in skeletal muscle 
as compared with PRT alone. Multiple studies have shown greater improvements in strength when 
Cr supplementation is combined with whole body PRT in older adults [49-51]. Results from a 
meta-analysis undertaken by Devries and Phillips [37] indciated that Cr supplementation during 
PRT enhanced the gain in LBM, strength, and functional performance over PRT alone in older 
adults. Similarly, Brose and colleagues [46] reported significant increases in total body mass, fat-
free mass, and isometric knee extension strength following 14 weeks of whole body resistance 
training plus Cr supplementation. Furthermore, after a six-month randomized controlled trial, 
researchers reported that Cr supplementation combined with PRT significantly increased 
appendicular lean mass, maximal strength, and muscle function to a greater extent than PRT alone 
in vulnerable older adults [47].
7Cr supplementation combined with PRT also has beneficial effects on bone health. In older men, 
10 weeks of Cr supplementation (0.1g/kg)  combined with a structured PRT completed three times 
per week led to a significant reduction in bone resorption by 30% (assessed using the bone 
biomarker NTx), compared to a non-significant increase of 13% in the placebo group [48]. These 
results support previous findings from Chilibeck et al. [49], showing Cr supplementation (0.3g/kg 
for 5 days, 0.07g/kg for 79 days) during 12 weeks of supervised PRT in healthy older males 
significantly increased upper-limb bone mineral content (BMC) by 3.2%, compared to a non-
significant decrease in the placebo group. Given that bone turnover is a relatively slow process 
typically requiring 9 months to detect changes [50, 51], these findings are somewhat remarkable. 
While several studies have indicated potential benefits from Cr supplementation on bone health, 
others have found no effect. Lobo et al. [52] investigated the effects of long-term, low-dose Cr 
supplementation (1g/day) without exercise for 52 weeks on bone health in postmenopausal women 
and found that Cr had no greater effect on bone mineral density (BMD) or bone microarchitecture 
compared to placebo. Additionally, Gualano et al. [47] showed no additional benefit of Cr 
supplementation (20 g/day for 5 days + 5 g/day for 24 weeks) to PRT on lumbar spine, proximal 
femur or whole body BMD, or serum bone markers in postmenopausal women. Further, Brose et 
al. [50] found no effect from Cr supplementation (5g/day) on serum osteocalcin (indicator of bone 
formation) in healthy older men following a 14-week PRT program. As it stands, results are mixed 
in relation to Cr and bone health. Notably, studies employing higher volumes of resistance training 
(i.e. greater number of sets per muscle group per week) combined with Cr supplememtation appear 
to have a beneficial effect on LBM, muscle strength and physical function and bone health in older 
8adults [37]. However, longer term studies (>12 months) with rigourous methodology utilising 
higher training volume with Cr are warranted. 
Table 1: Select studies examining the effects of Cr supplementation in healthy aging/clinical 
populations
Authors 
(year)
Patient/ 
subjects
Dosage Protocol 
duration
Exercise 
program
Results Adverse 
Effects
Healthy 
Aging
Brose et al 
(2003) [46]
28 older 
adults
5 g/day + 2 
g of dextrose
14 weeks 3 day/wk, 3 
x 10 total 
body
↑ Total body 
mass; ↑ FFM; ↑ 
Iso knee ext.
None 
reported
Candow et 
al 
(2008)[48]
40 older men 0.10 
g/kg/day
10 weeks 3 day/wk, 3 
x 10 total 
body
↑ Upper body 
1RM **; ↔ 
Lower body 
1RM, ↓ 30% 
bone 
resorption, PLA 
↑ 13% bone 
resorption
None 
reported
Stout et al 
(2007) [42]
15 older 
adults
20 g/day for 
7 days then 
10g/day
14 days of 
Cr v PLA 
with 4-6 
n/a Cr ↑ GRIP and 
PWCFT v PLA 
None 
reported
9weeks 
crossover 
Gotshalk et 
al (2001) 
[45]
20 older men 0.3g/kg/day 7 days n/a ↑ 1RM, ↑ LBP, 
↓ 
STS, ↓ TG.
None 
reported
Chilibeck et 
al 
(2005)[49] 
29 older men 0.3g/kg/day 
for 5 days, 
0.07 
g/kg/day for 
79 days
12 weeks 3 day/wk, 3 
x 10 total 
body
Cr ↑Upper limb 
BMC. ↔Legs, 
trunk or WB 
BMC. 
None 
reported
Gualano et 
al 
(2014)[47]
60 older 
women
20 g/day for 
5 days + 5 
g/day for 24 
weeks
24 weeks 2 day/wk, 3 
x 8-12 total 
body
↔ Lumbar 
spine, proximal 
femur or WB 
BMD
None 
reported
Lobo et al 
(2015)[52]
109 post-
menopausal, 
osteopenic 
women
1 g/day 12 months n/a ↔ Lumbar 
spine, total hip 
or WB BMD
None 
reported
Gualano et 
al 
(2014)[47]
60 older 
women
20 g/day for 
5 days + 5 
g/day for 24 
weeks
24 weeks 2 day/wk, 3 
x 8-12 total 
body
↑ appendicular 
lean mass; ↔ 
fat mass. 
None 
reported
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Clinical 
Populations
Andrews et 
al(1998) 
[53]
20 patients 
with chronic 
heart failure
20g/day 5 days n/a ↑ contractions 
before fatigue 
at 75% MVC; ↓ 
lactate % 
ammonia at 
75% MVC
None 
reported
Louis et al 
(2003)[54]
15 boys with 
MD
3g/day 3 months 
Cr and 3 
months 
PLA 
separated 
by 2 
months 
washout.
n/a ↑ MVC, TTE, 
BMD in 
ambulatory 
patients. 
↓ urinary 
excretion of 
cross-linked N-
telopeptides of 
Type I collagen
None 
reported
Tarnopolsky 
et al 
(2004)[55]
30 boys with 
MD
0.10 
g/kg/day
4 months 
Cr and 4 
months 
PLA 
separated 
by 6 week 
washout.
n/a ↓ urinary 
excretion of 
cross-linked N-
telopeptides of 
Type I 
collagen**
None 
reported
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Sakkas et al 
(2009)[56]
Patients with 
HIV infection
20 g/day for 
5 days then 
5g/day
12 weeks 3 day/wk, 4 
x 8 total 
body 
Greater ↑ LBM 
in Cr vs PLA.
None 
reported
Walter et al 
(2000) [87]
36 patients 
with muscular 
dystrophy
10.6 g/day 
for 10 days 
then 5 .3 
g/day for 46 
days
8 weeks n/a ↑ muscle 
strength
None 
reported
Tarnopolsky 
et al (2004) 
[58]
30 boys with 
muscular 
dystrophy
0.10g/kg/da
y, 
4-month 
supp, 6-
week 
wash-out, 
4 month 
PLA
n/a ↑ handgrip 
strength
n/a
BMC: Bone mineral content; BMD: Bone mineral density; BW: Bodyweight; Cr: creatine supplementation; g: gram; kg: kilogram; 1RM: 1 
repetition maximum; FFM: Fat free mass; GRIP: maximal isometric grip strength; Iso: isometric; LBM: lean body mass; LBP: lower body power; 
MD: muscular dystrophy; MVW: maximum voluntary contraction; PWCFT: physical working capacity at fatigue threshold; PLA: placebo group; 
STS: sit-to-stand test; TG: tandem gait test; TTE: time to exhaustion; WB: whole body; n/a: not applicable; ↑: increase; ↓: decrease;  ↔: no 
change;  **compared to Placebo   
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3.2Clinical populations
Studies involving both human and animal models with various catabolic diseases have shown 
evidence of increased LBM, bone density, muscle strength, and exercise performance following 
Cr supplementation. HIV-infected persons often experience a loss of LBM [57], which has been 
associated with accelerated disease progression and increased morbidity. A 2009 study by Sakkas 
et al. [56] found that 14 weeks of Cr supplementation (20g/d for the first 5 days, followed by a 
maintenance dose of 4.8 g/day), combined with progressive PRT for 12 weeks produced a greater 
increase in LBM compared to the placebo + PRT group in patients with HIV infection. 
Abnormalities of skeletal muscle in chronic heart failure patients include early onset of anaerobic 
metabolism and a swift depletion of PCr [58, 59]. In addition to abnormalities of PCr during 
exercise, patients with chronic heart failure have demonstrated a reduction in resting muscle Cr 
content and a delay in resynthesis of PCr post-exercise [60, 61]. Andrews et al. [53] examined the 
effects of Cr supplementation (20 g daily for 5 days) on repeated submaximal handgrip 
contractions in elderly men with chronic heart failure. The authors found a significant increase in 
the number of contractions performed before exhaustion at 75% maximum voluntary contraction 
(MVC) workload following Cr supplementation. Additionally, ammonia and lactate 
concentrations at the 75% MVC workload were significantly lower.
Muscular dystrophy is a genetic disease leading to muscle atrophy and bone loss. Researchers have 
examined the effects of three months of Cr supplementation (3g/day) in boys with Duchenne and 
Becker muscular dystrophy [54]. Participants in the Cr group who were able to walk during the 
intervention saw a significant decrease in urinary excretion of cross-linked N-telopeptides of Type 
13
I collagen, an indicator of bone resorption, whereas participants in the placebo group experienced 
a 6% increase. Cr supplementation also increased lumbar spine and whole-body BMD (assessed 
via dual energy X-ray absorptiometry, DXA) by approximately 3.8% and 2%, respectively. No 
effect was found in wheelchair-dependent individuals. Given the length of the normal bone 
remodelling cycle, one could hypothesize an even greater increase in BMD following a longer 
intervention [51].
Tarnopolsky et al. [55] investigated the effects of Cr supplementation (0.1g/kg) in young boys 
with Duchenne muscular dystrophy for 4 months. Although no changes in whole body BMD or 
BMC were observed, Cr supplementation did attenuate the increase in urinary excretion of cross-
linked N-telopeptides of Type I collagen by 22% compared to placebo. In addition, Kley et al. [62] 
conducted a meta-analysis on Cr and muscle disorders and concluded that Cr supplementation 
given to patients with muscular dystrophies led to significant increases in LBM, as well as 
maximum voluntary contraction, compared to placebo. 
Differences in dosing, length of intervention, population being studied, and use of a PRT protocol 
may explain some of the discrepancies among studies. Taken collectively, results from the 
literature on Cr supplementation in healthy aging/clinical populations that demonstrate similar 
muscle wasting characteristics often experienced by cancer patients (sarcopenia and cachexia) 
indicate that Cr supplementation combined with PRT can result in superior improvements in 
muscle mass, muscle strength and physical function. These findings are promising, though more 
research is warranted to see if similar improvements are observed in individuals with cancer, 
particularly those at a heightened risk of muscle wasting. 
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4.Musculoskeletal dysfunction in cancer
Individuals with cancer are exposed to a variety of cancer-specific factors that result in decrements 
in muscle mass and function, such as tumor-related factors, cancer therapies (in particular certain 
hormone and chemotherapies), malnutrition, physical inactivity along with increasing age and 
comorbidities [1-6]. To date, the primary focus of research around muscle toxicity has been 
confined to cachexia. Importantly, sarcopenia is also a chief concern in this population, particularly 
given the implications of decreased muscle mass and strength on the incidence and prevalence of 
treatment toxicity and associations with poorer prognosis in lung cancer [63], colorectal cancer 
[64], pancreatic cancer [65, 66] and renal cell carcinoma [1, 63, 67].  Sarcopenia and cachexia are 
somewhat distinct in their etiology, though they can be interrelated in a cancer context whereby a 
sarcopenic patient can become cachectic, or cachexia can exacerbate sarcopenic symptoms, further 
depleting already low levels of muscle mass. Regardless, reductions in muscle mass and strength 
are associated with profound decrements in quality of life and independence, greater toxicity from 
treatment and all-cause mortality. The prevalence of muscle dysfunction varies based on the type 
and stage of cancer, treatment received and methodology of measurement. 
4.1Sarcopenia
Sarcopenia refers to the age-related loss of muscle mass and function that typically accelerates 
with advancing age [3]. Characterized by changes in tissue quality, decreases in satellite cells, 
denervation and/or atrophy of type II muscle fibers and an increase in myosteatosis (fat infiltration 
in skeletal muscle); sarcopenia is associated with impairments in muscle strength, physical 
function and may increase the risk of falls [68-70]. Sarcopenia may be of particular relevance in 
15
cancer, whereby many individuals are diagnosed at an older age, often presenting with sarcopenic 
characteristics at diagnosis. Prevalence of sarcopenia in different types of cancer and stages of 
disease has not been well defined in the oncology literature, likely compounded by lack of 
universal diagnostic criteria [3]. Nevertheless, prevalence of sarcopenia in individuals with cancer 
can range from 11-74% depending on the diagnostic criteria and methods of assessment [71-75].
4.2Cachexia
Cachexia is distinct from sarcopenia in that it is a more aggressive form of muscle wasting, 
characterized by profound, unintentional weight loss (muscle and fat mass) that cannot be fully 
ameliorated with nutritional interventions [5, 76, 77].  Indeed, development of cachexia further 
depletes already low muscle mass, thereby exacerbating the development of sarcopenia. Criteria 
for diagnosis of cachexia are a topic of ongoing discussion, though such criteria include weight 
loss >5% in the past 6 months [76]. A discussion of the mechanisms of cachexia is beyond the 
scope of this review, and for further information readers are referred to reviews by Tisdale [78] 
and Aoyagi et al. [79] Briefly, this severe muscle wasting syndrome is thought to be a result of a 
combination of factors, including systemic inflammation, tumor metabolism and tumor-mediated 
effects, along with malnutrition and physical inactivity [76]. Cachexia is a major cause of 
morbidity and mortality, and management of weight loss and cachectic symptoms are of high 
clinical importance to minimize the impact of this syndrome [76, 80]. 
4.3Body composition
Cancer treatments are also associated with poor body composition, through loss of muscle mass 
and/or increase in fat mass. Chemotherapy is regularly associated with increased adiposity during 
16
treatment, with some studies demonstrating significant increases in body fat percentage up to a 
year following the cessation of treatment [81-86]. Accumulation of fat mass and/or loss of muscle 
mass have been documented in prostate cancer patients undergoing androgen deprivation therapy 
(ADT) [87-89]. Moreover, the use of corticosteroids to manage cancer and treatment side effects 
is associated with weight gain and redistribution of body fat [90]. Indeed, Cushingoid features 
(truncal obesity, dorsocervical and facial adiposity) can develop within the first two months of 
glucocorticoid therapy [90]. 
Several mechanisms for the adverse changes in body composition with cancer treatments have 
been proposed including lower levels of physical activity, development of menopause (in breast 
cancer), and treatment-related metabolic perturbations [84]. Importantly, there is increasing 
evidence that  poor body composition and specifically, low muscle mass can increase severity of 
treatment toxicities [18-20]. Moreover, impairments in muscle mass can predispose individuals to 
a loss in physical function and the ability to perform activities of daily living, increase the risk of 
falls and fractures, leading to a reduction in independence and quality of life (QoL), and an 
increased risk of mortality [68-70, 91-94]. Clearly, identification of novel strategies to maintain or 
improve muscle mass and strength is of high priority and clinical importance. 
There is strong evidence suggesting Cr supplementation can promote the overexpression of genes 
and proteins related to muscle hypertrophy [95, 96], as well as satellite cell activation [34]. Olsen 
et al. [34] reported that in healthy humans, Cr supplementation in combination with PRT amplified 
the increase in satellite cell number and myonuclei concentration in skeletal muscle fibers, thus 
facilitating muscle growth and hypertrophy. Cr has also been shown to enhance expression of 
17
myogenin and other myogenic regulatory factors that regulate myosin heavy chain expression, 
affecting the contractile protein content (actin and myosin) [97]. The growth-promoting effects of 
Cr may be extremely useful in situations where anabolic activity is suppressed, such as muscle 
wasting diseases, ageing populations, and cancer patients. 
4.4Bone health  
Cancer induced bone loss is indicated in the majority of cancers, with a variety of interrelated 
factors from dietary and physical activity patterns, loss of muscle mass, cancer cells, cancer 
therapies (particularly chemotherapy and hormone therapy) and metastatic disease [98, 99]. 
Indeed, reductions in bone health compounds muscle wasting by contributing to the loss of overall 
lean body mass, poor physical functioning, and increased risk of fractures. Perturbations in the 
tightly coupled process of osteoclast-mediated bone resorption and osteoblast-mediated bone 
formation are common in a variety of cancers, particularly in a metastatic context, leading to a loss 
of structural integrity and subsequent skeletal complications [98, 100, 101]. This greater rate of 
bone turnover is likely due to an increase in osteoclast activity and bone resorption, coupled with 
a decrease in osteoblast activity (bone formation); though the inverse can also be true in some 
metastatic environments [98, 102-104]. Indeed, adverse changes in BMD coupled with a 
deterioration in bone quality and microarchitecture increases fracture risk due to heightened bone 
fragility.[98, 99, 103, 105, 106] Emerging evidence suggests Cr monohydrate may positively affect 
bone physiology, possibly by increasing the activity of osteoblast-like cells involved in bone 
formation [107, 108] and decreasing bone resorption.[48, 54, 55]
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5.Cr supplementation in cancer patients
The few studies examining the effects of Cr in cancer patients have been mixed, with some 
showing no effect while others show some clinically meaningful benefit. A summary of these 
studies can be found in Table 2. Jatoi et al. [28]  examined Cr supplementation in 263 colorectal 
cancer patients experiencing “anorexia/weight loss syndrome”. In this trial, incurable patients were 
randomly assigned to either Cr (20g/day load x 5 days followed by 2 g/day) or placebo powder 
with identical dosing. Body weight was assessed weekly for one month and thereafter monthly 
while the patient remained on Cr or placebo. Appetite, QoL, and grip strength were also assessed. 
The primary endpoint was the percentage of patients who gained 10% of their baseline weight 
by 1 month. Out of 263 patients, only 3 gained 10% of their baseline weight over 1 month: two 
in the Cr group, and one in the placebo group. No significant differences in any of the measured 
variables were observed between the two groups. One possible explanation for lack of significant 
findings is the absence of a training stimulus. It is hypothesized that Cr uptake by skeletal muscle 
is modulated by muscle activity.[32] Muscle inactivity may contribute to a decrease in Cr uptake, 
and therefore compromise the effect of Cr supplementation on body weight and strength. 
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Table 2: Studies examining Cr supplementation in a cancer context. 
Authors 
(year)
Patients Dosage Protocol duration Exercise 
program
Results Adverse 
Effects
Jatoi et al 
(2017)[28]
362 cancer 
patients 
with 
weight loss 
syndrome
20 g/day for 5 
days then 
2g/day
9 months n/a ↔ body 
weight
None 
reported
Bourgeois et 
al 
(2008)[109]
Children 
with ALL 
undergoing 
chemother
apy
0.10 g/kg/day 2 x 16 weeks 
separated by 6 
week wash-out 
period.
n/a ↓ BF% Cr,  
↑ BF% NH
↔ BMD 
Cr
None 
reported
Norman et al 
(2008)[110]
Colorectal 
cancer 
patients 
undergoing 
chemother
apy
20g/day for 7 
days then 
5g/day
8 weeks n/a ↑ body cell 
mass; ↑ 
cell 
integrity
None 
reported
20
Lonbro et al 
(2012)[23]
30 Head 
and neck 
patients 
treated 
with 
radiotherap
y
5g/day + 30g 
Pro/day 
12 weeks 3 day/wk, 
3 x 10 
total 
body
↑ LBM 
PROCR 
group,ns↑ 
PLA ↔ 
Muscle 
Strength**
, ↔ 
Physical 
function**
None 
reported
ALL: acute lymphoblastic leukemia; BF%: body fat percentage; BMD: bone mineral density; Cr: creatine supplementation; g: gram; kg: 
kilogram; LBM: lean body mass NH: natural history group; PLA: placebo; PROCR: Protein + creatine supplementation; n/a: not applicable; ↑: 
increase; ↓: decrease;  ↔: no change; **compared to Placebo.  
Norman et al. [110] investigated the effects of 8 weeks of Cr supplementation on muscle function, 
body composition and QoL in colorectal cancer patients. Patients were randomized to receive 
either Cr monohydrate or a placebo. Patients in the Cr group received 20g/d for the first 7 days, 
followed by 5g/d as a maintenance for the remainder of the study. Following 8 weeks of 
supplementation, neither the Cr nor control group improved in assessments of body composition, 
muscle function, or QoL. Importantly, this study had no exercise component across the 8 weeks. 
Bourgeois and colleagues [109] investigated the effects of Cr supplementation with children on 
maintenance chemotherapy for acute lymphoblastic leukemia for two periods of 16 weeks 
separated by a 6-week “wash out” period. Participants in this study were also subject to 
corticosteroid therapy as part of their cancer treatment. The authors found no effects of Cr 
supplementation on body weight, lumbar spine BMD, whole body BMC or LBM. However, Cr 
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supplementation was associated with a reduction in body fat in supplemented patients. This is an 
important clinical finding considering those in the control group experienced a significant increase 
in body fat across the duration of treatment. Lonbro et al.[23] examined feasibility and efficacy of 
12 weeks of PRT in combination with protein and Cr supplementation (PROCR) in head and neck 
cancer patients.[23] Patients were randomized into two groups: A PROCR group undergoing a 
seven-day pre-trial creatine loading protocol (20g/day for 7 days) followed by 12 weeks of PRT 
with Cr (5g/day) and protein (30g/day) supplementation and a placebo (PLA) group undergoing a 
seven-day pre-trial placebo ingestion protocol followed by an identical PRT protocol with placebo 
supplementation. LBM increased non-significantly (1.3 kg) in the PLA group and increased 
significantly (2.6 kg) in the PROCR group. Though there were no statistically significant 
differences between groups at 12 weeks, given the dramatic losses of LBM seen in this patient 
population, the numerical two-fold (but not statistically signifcant) increase in LBM difference 
between groups should be viewed as having potentially large clinical significance. Though 
speculative, given that both groups consumed similar amounts of protein (as reported by mean 
values across the intervention) throughout the study (despite supplementation in the PROCR 
group), the Cr in the PROCR may have contributed to the additional LBM accrued in the PROCR 
group.
6.The potential therapeutic role of Cr Supplementation to treat cancer-related physical 
impairments. 
The combination of cardiovascular, musculoskeletal, and neurological impairments experienced 
by individuals with cancer, coupled with cancer-related fatigue, can result in deleterious effects on 
physical function.[92] Indeed, individuals with cancer can often present with low physical function 
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status at the onset of treatment, or experience severe deterioration over the course of 
treatment.[111-113] Reductions in performance measures such as gait speed, stair climbing ability 
and timed up and go are regularly seen amongst cancer patients and survivors, particularly when 
compared to apparently healthy controls.[114-116] Undoubtedly, these decrements in physical 
function are inextricably linked to the decline of force-generating capabilities of skeletal muscle. 
Impairments in muscle strength and an increase in fatigability are regularly reported in patients 
following cancer treatment.[115]  Burden et al.[117] found that in a sample of 87 early-stage 
colorectal patients, about half (54%) had a handgrip strength <85% below the reference 
range.[118] Advanced prostate cancer patients undergoing ADT have shown 29% lower handgrip 
strength compared to healthy controls. Further, breast cancer survivors have displayed lower 
muscle strength (20-30%) in multiple upper body exercises compared with healthy 
individuals.[119] The clinical implications of these reductions in muscle strength and physical 
function in individuals with cancer are of critical importance, as those with lower levels of physical 
function are more likely to experience premature mortality than those with higher physical 
function.[92-94] Galvao et al.[120] proposed a theoretical model of the role of PRT to improve 
musculoskeletal fitness, resulting in an increase in physical reserve capacity in men treated with 
ADT. Here, we propose that Cr supplementation in addition to PRT may provide even more 
improvements in musculoskeletal fitness, results in a greater increase in physical reserve capacity 
(Figure 2). The changes have important implications in preserving physical function with age, and 
reducing the risk of falls and fractures amongst individuals with cancer.
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Figure 2. Theoretical model of the role of RT and Cr to attenuate musculoskeletal fitness decline 
in individuals with cancer.(Modified from Galvao et al. Prostate Cancer Prostatic Dis 2008) 
Certain cancer therapies can exacerbate declines in muscle mass and strength, leading to an 
accelerated decline in physical function toward a “disability” condition, or lack of independence. 
It has been proposed that PRT may delay this decline through increases in muscle mass, strength 
and functional ability. Here, we suggest that Cr supplementation in addition to PRT may lead to 
further improvements, potentially delaying this decline even longer. (print in color)
To date, only one trial has investigated the effects of Cr supplementation on physical function in 
individuals with cancer. The results of the DAHANCA 25A trial [23] in head and neck cancer 
patients that received radiotherapy, demonstrated that PRT increased muscle strength and 
functional performance with no additive effect of protein and Cr supplementation on physical 
function. However, the authors urged caution in interpretation of the results due to the low number 
of participants, minimal supervision during the training sessions, and adherence to the supplement 
only being reported using a questionnaire. 
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While the physiological mechanisms linking Cr supplementation to an increase in exercise 
performance are yet to be fully elucidated, one possibility is an increase in PCr content in Type II 
muscle fibers. PCr content is 5-15% higher in Type II than Type I fibers.[121, 122] Additionally, 
the rate of PCr degradation is faster in Type II than Type I fibers during high-intensity, short 
duration activities.[121] Conversely, Type I fibers resynthesise PCr at a faster rate than Type II 
fibers during recovery periods. After Cr supplementation, both fiber types increase total and PCr 
content, with a trend toward a larger increase in Type II fibers.[123] Type II muscle fibers are 
associated with higher anaerobic ATP turnover rate and peak power output during exercise. 
Evidence suggests that fatigue during intense muscle contraction may be attributable to the 
utilization of PCr, specifically in Type II muscle fibers.[124] Therefore, any mechanism capable 
of increasing intramuscular Cr stores may help to prevent PCr depletion, and delay fatigue, during 
intense exercise. 
Earlier work by Harris et al.[32]  showed increases in skeletal muscle Cr content by 20-50% 
following Cr supplementation, with 20% of the increase in Cr accounted for by increases in PCr. 
Although it is unclear whether or not cancer patients experience a significant decrease in PCr 
stores, there is evidence in clinical populations with muscle atrophy demonstrating depletion of 
intramuscular stores of PCr in Type II muscle fibers.[125] Therefore, while further research is 
needed in individuals with cancer, results from other clinical populations and muscle wasting 
diseases suggest it is plausible that Cr supplementation may have beneficial effects on muscle 
function and performance in this patient population. 
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7.Which cancer groups are most likely to benefit from Cr supplementation
The heterogeneity of cancer type, treatments, definitions of sarcopenia and cachexia, along with 
methods of assessment, makes it difficult to accurately define the prevalence of muscle wasting in 
cancer. Pamoukdjian et al.[72] indicated that patients with local oesophageal cancer and small-cell 
lung cancer represented the highest prevalence of pre-therapeutic sarcopenia, with respective 
values of 75% and 79.2%.  In a study of 390 cancer patients, Sun et al.[126] found the highest 
prevalence of cachexia in pancreatic cancer (98.9%), gastric cancer (76.5%) and esophageal cancer 
(52.9%).  Geriatric cancer patients are particularly vulnerable, given the already low muscle mass 
in this population. Indeed, Prado et al.[127] found 68% of cancer patients with sarcopenia were 
over the age of 65. Additionally, certain cancer treatments can result in muscle loss and 
dysfunction, such as ADT for prostate cancer.[88] 
Certainly, given the results of studies in healthy aging and other clinical populations, any 
individual with cancer engaging in resistance training stands to benefit from Cr supplementation. 
Nevertheless, there may be subsets of cancer types, or treatments that may see greater benefit with 
Cr supplementation. Indeed, the highest prevalence of weight loss and cachexia has been observed 
in head and neck, pancreatic, lung, colorectal and gastric cancer.[3, 127] Older adults may be 
particularly vulnerable to muscle loss and could potentially benefit from Cr supplementation. 
Additionally, those undergoing certain treatments such ADT for prostate cancer are at a higher 
risk for muscle loss indicating the potential utility of Cr supplementation. 
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8.Safety considerations
Despite the expansive research supporting Cr as a safe and highly effective nutritional supplement 
in healthy aging and individuals with neurological/muscle disorders,[25, 33] it remains largely 
misunderstood, with unsubstantiated claims of side effects such as kidney and liver damage and 
dehydration. Contrary to these claims, Cr supplementation has not been associated with any signs 
of renal impairment.[25, 33, 128] Indeed, the safety of Cr supplementation on kidney function as 
measured by glomerular filtration rate has been demonstrated in a variety of apparently healthy 
and clinical populations.[129-132] In fact, Cr supplementation is being considered as a means to 
improve musculoskeletal and neurological functioning in patients with chronic kidney disease.[27] 
Long-term Cr supplementation has been investigated in other clinical populations such as 
Parkinson’s disease and Huntington’s disease, in studies ranging from 2-5 years, and doses up to 
10g/day, with no adverse effects of supplementation or impact on renal dysfunction reported. [133-
135] 
Further, studies of Cr supplementation have reported no adverse effects on hydration status or 
muscle cramps. Researchers have conducted a meta-analysis and reported no evidence of altered 
hydration status or thermoregulation following Cr supplementation.[136] Additionally, 
Greenwood et al [137] found no increase in dehydration, cramping, and/or muscle injury rates 
among college football players following long-term (3 years) Cr supplementation. Cr is one of the 
most rigorously studied supplements to date, with hundreds of studies demonstrating safety, 
tolerability, and wide ranging health and performance benefits.[25, 33] Moreover, there is no 
compelling evidence that short- or long-term Cr supplementation has any detrimental effects on 
kidney function, gastrointestinal distress, muscle dysfunction or hydration status.[25, 33, 129-132] 
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It should be noted however, that given the paucity of research examining Cr supplementation in 
patients with cancer, studies examining the safety and tolerability of Cr in a cancer context, in 
particular interactions with treatments such as radiation therapy, chemotherapy, steroid therapy 
and immunotherapy, are necessary. 
9.Conclusions and future directions
Given the beneficial effects of Cr supplementation on muscle mass, strength, BMD and physical 
function in a variety of clinical populations, the therapeutic potential for application in cancer is 
substantial. Indeed, randomized controlled trials are beginning to emerge, investigating the effects 
of Cr supplementation to attenuate cancer-related weight loss.[28] Nevertheless, application in 
various cancer contexts is still largely theoretical, with research in this area remaining sparse. 
Consequently, additional RCT’s are needed in this area to fully understand the impact of 
supplementation on clinically-meaningful outcomes in individuals with cancer, in particular those 
at a higher risk of muscle wasting, such as head and neck, pancreatic, and gastrointestinal cancers. 
The majority of studies in this area have examined Cr supplementation in isolation on clinical 
outcomes in individuals with cancer. Importantly, the beneficial effects of Cr supplementation are 
more likely a result of an increase in intramuscular Cr stores allowing an individual to get a greater 
“dose” of exercise, which can accumulate over time, leading to greater adaptations to exercise 
training (such as muscle mass, strength and physical function), than of the supplement alone. 
Accordingly, we recommend that future studies examine the effects of Cr supplementation in 
conjunction with resistance exercise on important clinical outcomes in individuals with cancer at 
a heightened risk of muscle loss (as mentioned above), such as muscle mass, strength and physical 
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function. Additionally, experiments in vitro or with animals are warranted to determine the 
mechanisms of effects of Cr to treat skeletal muscle toxicity in individuals with cancer. 
Collectively, further research in this area will allow for a greater understanding of the therapeutic 
effects of Cr supplementation in this patient population. 
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